Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated Trial
Trial Snapshot
- Phase
- Phase 2
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 54
- Locations
- 1
- Primary Endpoint
- Percentage change in body weight (kg)
Study Overview
Brief Summary
This study is an investigator-initiated, proof-of-concept, randomised, double-blind, placebo-controlled, parallel-group, single-centre clinical trial investigating the body weight loss potential of dapiglutide, a dual GLP-1R/GLP-2R agonist, administered subcutaneously once weekly. The study will investigate the efficacy of once-weekly subcutaneously administered of 4 mg and 6 mg dapiglutide versus placebo in 54 obese individuals (BMI >30 kg/m2) during a 12-week treatment period.
Detailed Description
In total, 54 obese participants with a body mass index (BMI) of ≥ 30 kg/m² are randomised to either treatment with the investigational medicinal product (IMP), being either dapiglutide 4 mg, dapiglutide 6 mg, or placebo for 12 weeks. To ensure blinding, the placebo arm is split between 4 mg and 6 mg placebo, making the randomisation sequence 2:2:1:1. The trial encompasses a 3-week screening period containing a screening visit (V1) to assess eligibility, followed by a randomisation visit (V2) and subsequently a 12-week treatment period concluded with a 4-week follow-up period. The IMP is subcutaneously administered in the abdomen once weekly from week 0 (V2) until week 12 (V14). The IMP is initiated at 2 mg once-weekly and up-titrated every third week with 2 mg until the respective trial doses are reached in each arm. Hereafter, the participants are kept at the dose level for the remainder of the trial (from week 3 and week 6 for the 4 mg and 6 mg doses, respectively). To reduce dropout in cases of low tolerability of the IMP, the investigator can postpone up-titration or down-titrate if judged necessary for participant retention or safety. The trial schedule will consist of five on-site visits, including screening, randomisation and a safety follow-up visit (four weeks after end of treatment (EOT)), in addition to a minimum of 10 telephone consultations. Therefore, the maximum trial duration is 16 weeks. For exploratory purposes, participants are invited to participate in a gastroduodenoscopy sub-study obtaining gastric and duodenal biopsies before and after treatment with IMP. A maximum of 7 participants from each treatment arm (total n=21) participate in this sub-study.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Masking Description
To ensure blinding, the placebo arm is split between 4 mg and 6 mg placebo, making the randomisation sequence 2:2:1:1 (e.i. 2x 4 mg dapiglutide, 2x 6 mg dapiglutide, 1x 4 mg placebo and 1x 6 mg placebo
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age 18-75 years
- •BMI ≥ 30 kg/m²
- •History of at least one attempt to lose body weight
Exclusion Criteria
- •A self-reported change in body weight ≥ 5% within the last 90 days prior to the screening visit
- •Treatment with any therapy, including endoscopic procedures and/or medication (e.g. liraglutide, bupropion/naltrexone and orlistat), intended for weight management within 90 days prior to screening
- •Previous, current, or planned (during the trial period) obesity treatment with surgery or a weight loss device < 1 year prior to screening
- •Glycated haemoglobin (HbA1c) ≥ 48 mmol/mol
- •History of type 1 diabetes or type 2 diabetes
- •Treatment with glucose-lowering agents within 90 days prior to screening
- •Compromised kidney function (estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2) at screening
- •Known liver disease (except for non-alcoholic fatty liver disease) and/or elevated plasma alanine aminotransferase (ALT) > three times the upper limit of normal at screening
- •History of acute and/or chronic pancreatitis
- •History and/or family history of medullary carcinoma and/or multiple endocrine neoplasia syndrome
- •Inflammatory bowel disease
- •Any history of colon cancer or intestinal polyps
- •Any history of intestinal stenosis
- •History of any other cancers (except margin-free resected cutaneous basal or squamous cell carcinoma or adequately treated in situ cervical cancer) unless disease-free state for at least five years
- •Uncontrolled thyroid disease as per discretion of the investigators
- •Any of the following: myocardial infarction, stroke, hospitalisation for angina and transient ischaemic attack within the last 60 days prior to screening
- •Class IV heart failure according to the New York Heart Association
- •Any concomitant disease or treatment that, at the discretion of the investigators, might jeopardise the participant's safety during the trial
- •Alcohol/drug abuse as per discretion of the investigators
- •Known or suspected hypersensitivity to the trial product or related products
- •Previous treatment with the trial product
- •Administration of an investigational drug within 90 days prior to screening
- •Simultaneous participation in any other clinical intervention trial
- •Mental incapacity or language barriers that preclude adequate understanding or cooperation, or unwillingness to comply with trial requirements
- •Use of GLP-1RA, GLP-2RA, dipeptidyl peptidase 4 (DPP) inhibitors, human growth hormone, somatostatin, or analogues thereof, within three months prior to screening
- •Known radiation enteritis or significant villous atrophy, e.g., due to active coeliac disease or inflammatory bowel disease
- •Regarding fertile men and women:
- •Women who are pregnant, breastfeeding, intend to become pregnant or are of childbearing potential will not be included in the study
- •Sterilised or postmenopausal women (> 12 months amenorrhoea or females ≥ 60 years of age) can be included
- •The following contraceptive methods are considered adequate for study enrolment of male participants: Surgically sterilised or willing to refrain from sexual intercourse from screening and until completion of the follow-up visit, or, if sexually active, condom usage and partner-practised contraception during the trial, i.e., from screening to the last visit
Arms & Interventions
Placebo (4 mg and 6 mg)
Abdominal s.c. self-administration of placebo content once weekly for 12 weeks. To ensure double-blinding, the placebo arm is divided into a 4-mg and 6-mg arm. But both placebo arms are pooled during data analysis.
Intervention: Placebo (Drug)
4 mg dapiglutide
Abdominal s.c. self-administration of 4 mg dapiglutide once weekly initiated at 2 mg and up-titrated after three weeks until the remaining nine weeks of treatment (12 weeks in total)
Intervention: Dapiglutide (Drug)
6 mg dapiglutide
Abdominal s.c. self-administration of 6 mg dapiglutide once weekly initiated at 2 mg and up-titrated after three weeks to 4 mg and again to 6 mg after six weeks until the remaining six weeks of treatment (12 weeks in total)
Intervention: Dapiglutide (Drug)
Outcomes
Primary Outcomes
Percentage change in body weight (kg)
Time Frame: From week 0 (baseline) to week 12 (end of treatment)
%-point
Secondary Outcomes
- Body weight reduction ≥ 10%(From week 0 (baseline) to week 12 (end of treatment))
- Body weight reduction ≥ 5%(From week 0 (baseline) to week 12 (end of treatment))
- Change in fasting serum/plasma concentrations of gut permeability biomarker (LPS-binding protein (LBP))(From week 0 (baseline) to week 12 (end of treatment))
- Change in fasting serum/plasma concentrations of inflammation markers (hs-CRP and IL-6)(From week 0 (baseline) to week 12 (end of treatment))
Investigators
Filip Krag Knop
Principal Investigator, Clinical Professor
University Hospital, Gentofte, Copenhagen